17-Mar-2020

March 2020 Shareholder Newsletter

Kazia Therapeutics is pleased to make its March 2020 newsletter available to investors.

02-Mar-2020

Dr James Garner interviewed for Switzer Financial Group’s The CEO Masterclass

Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.

28-Nov-2019

Interview with BioWorld

Our CEO, Dr James Garner was interviewed in BioWorld on the recent release of interim efficacy data from the phase II trial of GDC-0084 in glioblastoma as well as the overall GDC-0084 program.

14-Nov-2019

2019 Annual General Meeting Presentation Webcast

Kazia is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2019 AGM, together with questions and answers relating to the presentation.

29-Oct-2019

Dr James Garner discusses Kazia’s recent achievements with CommSec

Our CEO, Dr James Garner, sat down with CommSec’s Tom Piotrowski recently to discuss the company’s recent $4 million capital raising as well as key data readouts from Kazia’s clinical trials.

01-Oct-2019

Dr James Garner discusses Kazia’s recent achievements with Proactive Investors

Our Chief Executive Officer, Dr James Garner, sat down with Karen Tan from Proactive Investors in Sydney to discuss the company’s recent achievements and upcoming milestones.

26-Sep-2019

September 2019 Shareholder Newsletter

Kazia Therapeutics is pleased to make its September 2019 newsletter available to investors.

13-Sep-2019

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award

Kazia has been named as a winner in the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation & Growth Awards.

26-Jun-2019

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase

Watch Dr James Garner's recent presentation at the Gold Coast Investment Showcase.

24-Jun-2019

June 2019 Shareholder Newsletter

Kazia Therapeutics is pleased to make its June 2019 newsletter available to investors.

08-May-2019

Dr James Garner discusses Kazia’s Phase 2 trial in glioblastoma with Proactive Investors

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the release of new safety and tolerability data from the company’s phase IIa trial of GDC-0084 in newly-diagnosed brain cancer patients.

19-Apr-2019

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the Wholesale Investor Emergence event in Brisbane

Kazia CEO James Garner's recent presentation at the recent Wholesale Investor Emergence event in Brisbane.

25-Mar-2019

Kazia to present on Cantrixil at AACR 2019 meeting

Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting.  AACR is one of the top-tier academic conferences worldwide and will be held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA.

14-Feb-2019

February 2019 Shareholder Newsletter

Kazia Therapeutics is pleased to make its February 2019 newsletter available to investors.

13-Feb-2019

Dr Alan Olivero discusses what makes a good brain cancer drug

Dr Alan Olivero, who led the team at Genentech that developed GDC-0084, discusses what makes a good brain cancer drug.

12-Nov-2018

2018 Annual General Meeting Presentation Webcast

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2018 AGM, together with questions and answers relating to the presentation.

05-Nov-2018

November 2018 Shareholder Newsletter

Kazia Therapeutics is pleased to make its November 2018 newsletter available.

22-Oct-2018

Kazia enters clinical collaboration to study use of brain cancer drug GDC-0084 in breast cancer

The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.

13-Sep-2018

Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research

The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.

11-Jul-2018

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase recently. Dr Garner’s presentation provides an excellent snapshot of the company at present and what makes its current therapies under development – Cantrixil for recurrent ovarian cancer and GDC-0084 for glioblastoma multiforme – different from existing treatment options and others in the clinic.